cancer

UTSW Says Experimental Compound Kills Cancer, Spares Immune Cells

by | Jul 17, 2024

Researchers at UT Southwestern Medical Center in Dallas have identified a compound that selectively eliminates cancer cells while sparing immune cells in a form of cell death known as ferroptosis, according to a news release. 

UTSW said the findings, published in Science Translational Medicine earlier this year, could lead to new treatments for a wide variety of cancer types....

MORE►
CPRIT Approves Over $16M in Cancer-Fighting Grants to Dallas-Area Institutions
by | Feb 27, 2024
Included in the 12 Dallas-area funding awards is a $4 million Rising Star grant to bring Stefan Gloeggler, Ph.D., to UT Southwestern Medical Center from the Max Planck Institute of Multidisciplinary Sciences in Göttingen, Germany.
MORE►
Carson Leslie Foundation, Grant Halliburton Team Up to Support Kids With Cancer—And Deliver Smiles
by | Feb 22, 2024
Carson Leslie Foundation, Grant Halliburton Team Up to Support Kids With Cancer—And Deliver Smiles
MORE►
UTA Study Shows Machine Learning Technique Is 30% Better at Predicting Cancer Cure Rates
by | Dec 6, 2023
UT Arlington principal investigator Dr. Suvra Pal said that previous studies modeling the probability of a cancer cure—also called the cure rate—"used a generalized linear model." The new statistical modeling method published by Pal and his student is said to be 30% more effective in predicting who will be cured of cancer and who will need further treatment.
MORE►

Illustration: bsd555/iStock

CPRIT Awards $9.5M in Cancer Research Grants to SMU and Dallas’ Baylor Research Institute

by | Aug 17, 2023
The 29 new grants approved by CPRIT's Oversight Committee include the first CPRIT Scholar award to Southern Methodist University in Dallas and state funding for Dallas' Baylor Research Institute to join a major National Cancer Institute study.
MORE►
Simmons Cancer Center Investigators Get Nearly $15M in CPRIT funding
by | Mar 13, 2023
“Our researchers continue to push the envelope on developing a better understanding of cancer and new ways to help cancer patients in Texas and beyond,” said Center Director Carlos L. Arteaga, M.D.
MORE►
UTSW Researchers’ Discovery About Gut Bacteria May Improve Cancer Treatments
by | Mar 9, 2023
The researchers discovered how healthy bacteria can escape the intestine, travel to lymph nodes and cancerous tumors elsewhere in the body, and boost the effectiveness of certain immunotherapy drugs. “Now we understand that mechanism much better and, in the future, hope to use this knowledge to better fight cancer," said UT Southwestern's Andrew Y. Koh, M.D.
MORE►
Fort Worth Biotech NanOlogy Gets U.S. Patent for New Cancer Treatment
by | Mar 7, 2023
NanOlogy said the new patent covers a method of treating cancer by intratumoral administration of large surface area microparticle taxanes in combination with systemic administration of immune checkpoint inhibitors. “The goal is to identify which combinations can increase the immune response, thereby increasing the overall solid tumor response to treatment," said NanOlogy Chief Medical Officer Gere DiZerega.
MORE►

Financial Strategies Acquisition Corp. Acquires Preclinical Pharma Company

by | Feb 15, 2023

Dallas-based Financial Strategies Acquisition Corp. has acquired Texas-based preclinical pharmaceutical company Austin Biosciences Corp.

Financial Strategies is a special purpose acquisition company led by CEO Alexander V. Schinzing. It said that upon the deal’s closing, Austin Biosciences will become a wholly owned subsidiary of the company.

Earlier this month, Financial Strategies announced that its board approved an extension of the period of time available to consummate the deal by one month from Feb....

MORE►
McKesson Forms Joint Venture with HCA Healthcare to Fight Cancer
by | Jun 23, 2022
Two giants in their industry are teaming up to accelerate cancer research. The new joint venture is an "important step forward" to increase access to clinical trials, says McKesson CEO Brian Tyler, McKesson CEO. Separate from the joint venture deal, McKesson will acquire Genospace, a personalized precision medicine platform that’s part of HCA’s research institute.
MORE►
Dallas’ Lupagen Aims To Change the Way Cancer, Other Disorders Are Treated
by | Jun 2, 2022
Instead of shipping a patient's blood to a lab for customized cell therapy, Lupagen does the procedure "in vivo," using a dialysis-like treatment at the patient's bedside. Now it's collaborating with Umoja Biopharma to use its drug-delivery tech to place targeted immunotherapies in patients.

“We're able to deliver different types of gene therapies in a closed system," Lupagen's CEO says, calling the tech a "bridge to the future."
MORE►
Westlake’s Virbac Announces Availability of New Dog Cancer Treatment Across the U.S.
by | Aug 16, 2021
Stelfonta received FDA approval last November to treat dogs with non-metastatic, skin-based mast cell tumors (MCTs)—the most common malignant skin tumor in dogs. The injection is now available at vet clinics across the U.S., with an 88% "satisfactory experience" rate to date.
MORE►
grants

Image: Yurchello108/iStockPhoto

Mary Kay Foundation Gives $150K To Provide Cancer Resources To Underserved Female Populations

by | Jun 8, 2021
Dallas' Mary Kay Foundation has donated $150,000 to CancerCare to provide direct support to women who are most in need of financial or emotional assistance.
MORE►
Dallas’ Lantern Pharma Hits Major Milestone on its AI Platform to Advance its Oncology Drug Research and Development
by | Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
TWU Biology Team Granted a Patent for Anti-Cancer Compounds That Could Save Lives
by | Oct 15, 2020
The novel invention from researchers at Texas Woman’s University in Denton could greatly contribute to cancer treatment research. The compounds can prevent the growth of breast, lung, and colon cancer cells.
MORE►
Dialectic
Dialectic Therapeutics Plans to Further Cancer Drug Research Using $3M Seed Award
by | Feb 26, 2020
Using innovative new technologies and targeted therapies, the Dallas biotech startup aims to help patients with cancer, give them hope, and prolong their lives.
MORE►
A Special Thank you to our sponsors

A collaboration of the Dallas Regional Chamber and Dallas Next, Dallas Innovates is an online news platform covering what's new + next in Dallas - Fort Worth innovation.

© Copyright 2024 | All rights reserved.

Business

Creative

Education

Impact

Invention

Startup

Our Sponsors

Our Partners